A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RAG-17 in Subjects With Amyotrophic Lateral Sclerosis (ALS) With Superoxide Dismutase Type 1 (SOD1) Gene Mutation
RecruitingNCT06556394
Ractigen Therapeutics.Amyotrophic Lateral Sclerosis
Start: 2024-12-24End: 2026-04-30Target: 32Updated: 2025-01-08